Get started
Champions Oncology, Inc.Champions Oncology, Inc.Champions Oncology, Inc.

Champions Oncology, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

CSBR chart


Full chart

CSBR upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪104.34 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−0.04 USD
Net income (FY)
‪−7.28 M‬ USD
Revenue (FY)
‪50.16 M‬ USD
Shares float
‪5.98 M‬
Beta (1Y)
0.45

Employees


Employees (FY)
210
Change (1Y)
−20 −8.70%
Revenue / Employee (1Y)
‪238.83 K‬ USD
Net income / Employee (1Y)
‪−34.65 K‬ USD

About Champions Oncology, Inc.


Sector
Health Technology
Industry
Biotechnology
CEO
Ronnie Morris
Website
championsoncology.com
Headquarters
Hackensack
Founded
1985
FIGI
BBG000BYGPJ9
Champions Oncology, Inc. engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft, is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The company was founded by James M. Martell and David Sidransky on June 4, 1985 and is headquartered in Hackensack, NJ.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

CSBR news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Sparks


Curated watchlists where CSBR is featured.

See all sparks 

Frequently Asked Questions


The current price of CSBR is 7.51 USD — it has decreased by −0.60% in the past 24 hours. Watch Champions Oncology, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Champions Oncology, Inc. stocks are traded under the ticker CSBR.
CSBR stock has risen by 41.60% compared to the previous week, the month change is a 69.80% rise, over the last year Champions Oncology, Inc. has showed a 55.06% increase.
We've gathered analysts' opinions on Champions Oncology, Inc. future price: according to them, CSBR price has a max estimate of 8.00 USD and a min estimate of 8.00 USD. Watch CSBR chart and read a more detailed Champions Oncology, Inc. stock forecast: see what analysts think of Champions Oncology, Inc. and suggest that you do with its stocks.
CSBR reached its all-time high on Oct 1, 2018 with the price of 17.90 USD, and its all-time low was 1.11 USD and was reached on Aug 26, 2016. View more price dynamics on CSBR chart.
See other stocks reaching their highest and lowest prices.
CSBR stock is 7.06% volatile and has beta coefficient of 0.45. Track Champions Oncology, Inc. stock price on the chart and check out the list of the most volatile stocks — is Champions Oncology, Inc. there?
Today Champions Oncology, Inc. has the market capitalization of ‪103.71 M‬, it has increased by 9.59% over the last week.
Yes, you can track Champions Oncology, Inc. financials in yearly and quarterly reports right on TradingView.
Champions Oncology, Inc. is going to release the next earnings report on Mar 18, 2025. Keep track of upcoming events with our Earnings Calendar.
CSBR earnings for the last quarter are 0.05 USD per share, whereas the estimation was 0.01 USD resulting in a 400.00% surprise. The estimated earnings for the next quarter are −0.01 USD per share. See more details about Champions Oncology, Inc. earnings.
Champions Oncology, Inc. revenue for the last quarter amounts to ‪13.50 M‬ USD, despite the estimated figure of ‪13.05 M‬ USD. In the next quarter, revenue is expected to reach ‪12.90 M‬ USD.
CSBR net income for the last quarter is ‪728.00 K‬ USD, while the quarter before that showed ‪1.31 M‬ USD of net income which accounts for −44.55% change. Track more Champions Oncology, Inc. financial stats to get the full picture.
No, CSBR doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 21, 2024, the company has 210.00 employees. See our rating of the largest employees — is Champions Oncology, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Champions Oncology, Inc. EBITDA is ‪1.72 M‬ USD, and current EBITDA margin is −10.08%. See more stats in Champions Oncology, Inc. financial statements.
Like other stocks, CSBR shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Champions Oncology, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Champions Oncology, Inc. technincal analysis shows the buy rating today, and its 1 week rating is strong buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Champions Oncology, Inc. stock shows the strong buy signal. See more of Champions Oncology, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.